Both of these clinical outcomes are driven by substantial reductions in the cumulative incidence and time to onset of most diabetes-related complications due to the improvements in glycaemic control associated with insulin administration (Table 4, Table 5). The gene discussed is INS; the disease is diabetes mellitus.